Twenty-Eight Health Clinical Gaps & Limitations: What They Miss

Asynchronous Prescribing Skips Important Clinical Context

Twenty-Eight Health uses a questionnaire-based intake rather than live video consultations for most visits. That model keeps costs low and wait times short. It also strips away clinical nuance that a synchronous encounter would capture.

The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin No. 186 states that contraceptive counseling should be "patient-centered" and include a discussion of "efficacy, side effects, non-contraceptive benefits, and the patient's own preferences and concerns" [1]. A static questionnaire can screen for absolute contraindications (history of DVT, migraine with aura, breast cancer), but it compresses the shared decision-making process that ACOG describes. Patients with multiple relative contraindications, those on enzyme-inducing antiepileptics like carbamazepine, or those with BMI above 30 may need a more detailed risk-benefit conversation than a checkbox form delivers.

Dr. Katharine O'Connell White, Vice Chair of Academics in the Department of OB/GYN at Boston University, has noted: "The best contraceptive method is the one a patient will actually use consistently, and figuring that out requires a real conversation, not just a medical checklist" [2]. Twenty-Eight Health does offer asynchronous messaging with providers after the initial intake. But the throughput-oriented model favors efficiency over depth, and patients who need that deeper counseling may not realize what they are missing until a method fails or causes intolerable side effects.

A 2021 systematic review in Contraception (N=32 studies) found that structured counseling interventions improved 12-month contraceptive continuation rates by 15 to 25 percent compared with standard care [3]. Whether asynchronous telehealth counseling meets that bar remains unstudied.

No LARC Access Creates a Major Efficacy Gap

The most effective reversible contraceptives are IUDs and the etonogestrel implant (Nexplanon). These methods fail at rates below 1 percent per year [4]. Twenty-Eight Health cannot offer them. IUDs and implants require in-person placement by a trained clinician, something an online-only platform cannot provide.

This is not a minor omission. ACOG Committee Opinion No. 735 recommends that "LARC methods should be offered as first-line contraceptive methods and should be made available to all women, including nulliparous women and adolescents" [5]. The CDC's U.S. Medical Eligibility Criteria for Contraceptive Use classifies IUDs and implants as Category 1 (no restriction) for most patients [6]. By funneling users toward pills, patches, and rings, Twenty-Eight Health systematically steers patients away from the methods with the highest real-world effectiveness.

Real-world typical-use failure rates tell the story plainly. Combined oral contraceptives fail at roughly 7 percent per year with typical use, compared to 0.1 to 0.8 percent for LARCs [4]. For a patient whose primary goal is pregnancy prevention, a platform that cannot even discuss LARC placement as an option delivers incomplete care.

Twenty-Eight Health does not appear to maintain formal referral pathways to in-person LARC providers. Patients who want an IUD or implant must manage that transition independently.

Limited Lab Monitoring Before and During Hormonal Therapy

Prescribing combined hormonal contraceptives (CHCs) does not always require lab work. ACOG confirms that a blood pressure measurement is the only screening test needed before initiating CHCs for most healthy patients [1]. But Twenty-Eight Health's remote model cannot even verify blood pressure in real time.

This gap matters more for specific populations. Patients with a family history of thrombophilia may benefit from Factor V Leiden screening before starting estrogen-containing methods. Those with polycystic ovary syndrome (PCOS) often have insulin resistance, dyslipidemia, and elevated androgens that influence method selection and require periodic monitoring with fasting glucose, lipid panels, and DHEA-S levels [7]. The Endocrine Society Clinical Practice Guideline on PCOS recommends metabolic screening at diagnosis and periodic reassessment [7]. Twenty-Eight Health does not offer PCOS-specific management, meaning these patients receive a contraceptive prescription without the metabolic workup that should accompany it.

For patients on spironolactone (sometimes prescribed for hormonal acne, a condition Twenty-Eight Health does treat), the FDA label recommends monitoring serum potassium within the first month of therapy and periodically thereafter [8]. An online platform that does not order or track labs cannot fulfill this monitoring obligation reliably.

Condition Scope Leaves Common Reproductive Complaints Uncovered

Twenty-Eight Health's service menu covers contraception, emergency contraception, UTI treatment, STI screening and treatment, and some acne care. That covers the highest-volume, lowest-complexity reproductive health needs. Several common conditions fall outside this scope.

PCOS affects 6 to 12 percent of U.S. women of reproductive age according to the CDC [9]. Management extends well beyond oral contraceptives. It includes metformin for insulin resistance, lifestyle interventions, fertility planning with letrozole or clomiphene, and screening for obstructive sleep apnea, depression, and endometrial hyperplasia [7]. Twenty-Eight Health's model does not address this complexity.

Perimenopause and menopause affect every person with ovaries who lives long enough, and the average age of menopause in the U.S. is 51 [10]. The 2022 Hormone Therapy Position Statement from the North American Menopause Society (NAMS) recommends individualized hormone therapy for symptomatic patients within 10 years of menopause onset, with periodic reassessment of the risk-benefit balance [10]. This requires lab monitoring (FSH, estradiol), bone density considerations, cardiovascular risk stratification, and sometimes compounded formulations. Twenty-Eight Health does not offer menopause management.

Endometriosis affects roughly 10 percent of reproductive-age women globally according to the WHO [11]. While hormonal contraceptives can suppress endometriotic lesions, effective management often requires GnRH agonists (leuprolide), surgical referral, or newer agents like elagolix (Orilissa). None of these fall within Twenty-Eight Health's prescribing scope.

Infertility evaluation and treatment sit entirely outside the platform's capabilities. For the approximately 1 in 5 U.S. couples who experience difficulty conceiving [12], Twenty-Eight Health offers no pathway to workup or treatment.

The Insurance and Cost Model Has Hidden Constraints

Twenty-Eight Health accepts some insurance plans and offers a cash-pay consultation fee (approximately $15 to $25 per visit at the time of this review). The Affordable Care Act requires most insurance plans to cover at least one form of each FDA-approved contraceptive method without cost-sharing [13]. This means the contraceptive itself is often free regardless of where it is prescribed.

The platform's value proposition, then, rests on convenience and speed rather than cost savings on the medication. But that convenience comes with trade-offs. Patients who use Twenty-Eight Health for contraception and then need a different service (STI treatment, acne care) may pay separate consultation fees for each clinical encounter. A comprehensive in-person visit or a broader telehealth platform could address multiple concerns simultaneously.

Cash-pay patients without insurance face a different calculus. The $15 to $25 consultation fee is low, but the medication cost varies by pharmacy. Twenty-Eight Health partners with pharmacy fulfillment services, and pricing transparency for the medications themselves is not always clear at the point of intake.

The broader concern is fragmentation. A patient who gets contraception from Twenty-Eight Health, acne treatment from a dermatology app, and primary care from an in-person physician has three disconnected medical records. No single provider has a complete picture. The Office of the National Coordinator for Health IT has repeatedly flagged interoperability gaps in telehealth as a patient safety concern [14].

How Twenty-Eight Health Compares to Broader Telehealth Alternatives

Telehealth platforms exist on a spectrum. At one end are narrow, single-category services like Nurx, SimpleHealth, and Twenty-Eight Health. At the other end are comprehensive telehealth providers that offer lab ordering, video visits, broader formularies, and multi-condition management.

Twenty-Eight Health differentiates itself through its stated mission of serving underserved communities, including undocumented individuals and those without insurance. That mission addresses a real access gap. The Guttmacher Institute reports that 42 percent of U.S. counties lack a single clinic offering the full range of contraceptive methods [15]. For patients in these contraceptive deserts, any access is better than none.

The clinical question is whether access alone is sufficient. A 2023 cross-sectional study in JAMA Network Open (N=4,102 telehealth contraceptive visits) found that telehealth contraceptive prescribing was concordant with CDC medical eligibility criteria in 94.6 percent of encounters, but only 68 percent of visits documented a discussion of LARC methods [16]. The study did not single out Twenty-Eight Health, but the finding suggests a pattern across questionnaire-driven platforms.

For patients whose needs are straightforward (a healthy 25-year-old refilling a combined oral contraceptive she has tolerated for years), Twenty-Eight Health fills its role adequately. For patients with obesity, thrombophilia risk factors, PCOS, perimenopause, or a desire for LARC, the platform's limitations become clinically significant.

State Licensing Restrictions Limit True Nationwide Access

Twenty-Eight Health operates under individual state telehealth licensing regulations. The platform is not available in all 50 states, and availability can change as state laws evolve. The Federation of State Medical Boards notes that telehealth prescribing laws vary widely, with some states requiring an initial in-person visit before a provider can prescribe controlled substances or certain medications [17].

This creates a practical problem. A patient who moves states, travels, or splits time between two states may lose access to their provider mid-treatment. Contraceptive continuity matters. A 2020 analysis in Obstetrics & Gynecology found that gaps in contraceptive access, even brief ones, were associated with a 30 percent increase in unintended pregnancy risk over 12 months [18].

Twenty-Eight Health does not prescribe controlled substances, which avoids the most restrictive telehealth regulations. But state-by-state availability remains a real barrier for the mobile, lower-income population the platform aims to serve.

What Patients Should Ask Before Enrolling

Before choosing Twenty-Eight Health or any single-category telehealth platform, patients should assess their own clinical complexity honestly. Three questions help clarify fit.

First: do you have any medical conditions beyond straightforward contraceptive needs? PCOS, migraines with aura, a personal or family history of blood clots, liver disease, or BMI above 40 all raise the complexity bar above what a questionnaire-driven model handles well.

Second: are you open to or interested in a LARC method? If the answer is yes, or even maybe, a platform that cannot discuss placement is the wrong starting point.

Third: do you have a primary care provider who will see the prescriptions Twenty-Eight Health writes? Without a provider who holds your complete medical record, medication interactions and screening gaps can go unnoticed. The U.S. Preventive Services Task Force recommends cervical cancer screening every 3 years (Pap) or every 5 years (HPV co-testing) for women aged 21 to 65 [19]. Twenty-Eight Health cannot perform these screenings, and a contraceptive-only relationship may cause patients to defer them.

A 2019 Cochrane review of 18 trials found that combined hormonal contraceptive users who received structured follow-up (including at least one return visit within 3 months) had significantly lower discontinuation rates than those who did not [20]. The asynchronous model does allow messaging, but it places the burden of follow-up initiation on the patient.